Search results
Results from the WOW.Com Content Network
The Drug Rebate Equalization Act of 2009 (DRE), introduced in the 111th United States Congress by Representative Bart Stupak as H.R. 904, and in the Senate by Senator Jeff Bingaman as S. 547, sought to equalize the treatment of prescription drug discounts between Medicaid managed care and Medicaid fee-for
The California Medical Assistance Program (Medi-Cal or MediCal) is the California implementation of the federal Medicaid program serving low-income individuals, including families, seniors, persons with disabilities, children in foster care, pregnant women, and childless adults with incomes below 138% of federal poverty level.
Childhood arthritis (juvenile arthritis or pediatric rheumatic disease) is an umbrella term used to describe any rheumatic disease or chronic arthritis-related condition which affects individuals under the age of 16. There are several subtypes that differentiate themselves via prognosis, complications, and treatments.
According to estimates, juvenile idiopathic arthritis (JIA) affects 1 to 4 out of every 1000 children, making it the most prevalent rheumatic illness in children. [ 34 ] [ 35 ] With incidence rates ranging from 0.4 to 0.8 children per 100,000 children, sJIA accounts for 10% to 20% of JIA cases.
Logo of the Department of Health and Human Services. The Children's Health Insurance Program (CHIP) – formerly known as the State Children's Health Insurance Program (SCHIP) – is a program administered by the United States Department of Health and Human Services that provides matching funds to states for health insurance to families with children. [1]
Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis (JRA), [1] is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children. [3]
Many Medicare Advantage plans also offer prescription drug coverage (Part D). This means that generally, Medicare Advantage plans will cover osteoporosis drugs, such as Prolia.
Conventional DMARDs are known to be the first-line treatment for rheumatoid arthritis. [9] Treatment can be a monotherapy or in combination with other anti-arthritic medications. Common DMARDs include oral methotrexate, leflunomide, or sulfasalazine. Conventional DMARDs have a slow onset of action and can take 2–3 months to exhibit effect. [9]